| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725197 | Clinical Gastroenterology and Hepatology | 2018 | 27 Pages |
Abstract
In an analysis of reports on eluxadoline submitted to the Federal Adverse Event Reporting System, we confirmed a previously reported risk of pancreatitis associated with eluxadoline. The need for hospitalization in at least half of these instances and a recent report of 2 fatalities should prompt reassessments of the agent's risk-benefit ratio.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Andrew J. Gawron, Klaus Bielefeldt,